Development of a CE‐MS method for the study of riociguat and metabolite M1 in pharmaceutical analysis
Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and reso...
Saved in:
Published in | Electrophoresis Vol. 40; no. 22; pp. 2936 - 2945 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Wiley Subscription Services, Inc
01.11.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02. |
---|---|
AbstractList | Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60-5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pK
, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pK
= 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pK
= 4.40 ± 0.02. Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02. Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60-5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02.Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60-5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02. Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, pKBH, were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pKBH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pKBH = 4.40 ± 0.02. Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of riociguat and metabolite M1 as support for optimized CZE/MS assay. Fundamental separation parameters, such as peak width, symmetry, and resolution are studied in a series of ammonium formate buffers within pH range 2.60–5.61. The narrow region of peak symmetry lies close to pH 4.0 for both analytes. Accordingly, the value of resolution maximizes in a background electrolyte adjusted to pH 4.10. Basic calibration parameters estimated from CZE experiments with absorption photometric and mass spectrometric detection of riociguat and metabolite M1 were evaluated. More than three orders lower LOD was achieved with high resolution mass spectrometric detection. The observed difference in the sensitivity of both detection techniques gives priority to the utilization of CZE/MS in practice. The values of dissociation constants of riociguat and metabolite M1, p K BH , were determined from CZE measurements in lithium formate and lithium acetate background electrolytes with constant ionic strength. The value of pK BH = 4.30 ± 0.02 for riociguat corresponds well to the value already presented in the literature. According to our observation, metabolite M1 behaves like a slightly stronger base with estimated pK BH = 4.40 ± 0.02. |
Author | Bursová, Miroslava Čabala, Radomír Jelínek, Ivan Štícha, Martin Hložek, Tomáš |
Author_xml | – sequence: 1 givenname: Martin orcidid: 0000-0001-8008-7668 surname: Štícha fullname: Štícha, Martin organization: Charles University – sequence: 2 givenname: Tomáš surname: Hložek fullname: Hložek, Tomáš organization: Charles University and General University Hospital in Prague – sequence: 3 givenname: Miroslava surname: Bursová fullname: Bursová, Miroslava organization: Charles University and General University Hospital in Prague – sequence: 4 givenname: Radomír orcidid: 0000-0001-7022-1317 surname: Čabala fullname: Čabala, Radomír organization: Charles University and General University Hospital in Prague – sequence: 5 givenname: Ivan surname: Jelínek fullname: Jelínek, Ivan email: ivan.jelinek@natur.cuni.cz organization: Charles University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31520473$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0ctu1DAUBmALFdHpwJYlssSGzQzHt0m8RMNwkaYCqbCOHOek48qJg-2AZscj8Iw8CUlbuuhmvPHm-8-R_V-Qsz70SMhLBmsGwN-iH9KaA9MArGRPyIIpzld8U4ozsgBWiBWUQp2Ti5RuAEBqKZ-RczEpkIVYkOv3-BN9GDrsMw0tNXS7-_v7z-UV7TAfQkPbEGk-IE15bI6ziC5Ydz2aTE3fzMrUwbuM9JJR19PhYGJnLI7ZWeMnY_wxufScPG2NT_ji_l6S7x9237afVvsvHz9v3-1XVooSVsikLpTEmhnTcq1QNqIRViCUm6IWrGy4LRioumFaiemwuq0NM7zVLbeGiyV5czd3iOHHiClXnUsWvTc9hjFVXAjFeKk36jTlGjTc7lmS14_oTRjj9LTbgazQslDz7lf3aqw7bKohus7EY_X_tyewvgM2hpQitg-EQTXXWc11Vg91TgH5KGBdNtmFPkfj_MnYL-fxeGJJtdt_vSpAgfgH2emyvg |
CitedBy_id | crossref_primary_10_1002_elps_202000135 crossref_primary_10_1016_j_jpba_2022_115059 crossref_primary_10_1016_j_electacta_2024_144823 |
Cites_doi | 10.1002/elps.201600058 10.1016/j.jchromb.2006.03.015 10.2147/DDDT.S117277 10.1002/elps.200500260 10.1016/j.chroma.2004.02.087 10.1107/S2052520617006011 10.1007/s00508-016-1068-8 10.1002/elps.200405982 10.1007/s00216-010-3741-5 10.1002/phar.1592 10.1007/s40265-013-0149-5 10.1007/s40262-017-0604-7 10.1002/rcm.4458 10.4155/bio.14.257 10.1007/s13361-010-0037-0 10.1007/s40265-014-0317-2 10.5582/bst.2018.01081 10.1016/j.aca.2013.01.061 |
ContentType | Journal Article |
Copyright | 2019 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
Copyright_xml | – notice: 2019 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim – notice: 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7U5 8FD L7M 7X8 7S9 L.6 |
DOI | 10.1002/elps.201900181 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Solid State and Superconductivity Abstracts Technology Research Database Advanced Technologies Database with Aerospace MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Technology Research Database Advanced Technologies Database with Aerospace Solid State and Superconductivity Abstracts MEDLINE - Academic AGRICOLA AGRICOLA - Academic |
DatabaseTitleList | MEDLINE Technology Research Database AGRICOLA MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Chemistry |
EISSN | 1522-2683 |
EndPage | 2945 |
ExternalDocumentID | 31520473 10_1002_elps_201900181 ELPS7050 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: Ministry of Education, Youth and Sports funderid: CZ.02.1.01/0.0/0.0/15_003/0000417 – fundername: Ministry of Education, Youth and Sports grantid: CZ.02.1.01/0.0/0.0/15_003/0000417 |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1L6 1OB 1OC 1ZS 31~ 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52S 52T 52U 52W 52X 53G 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A03 AAESR AAEVG AAHBH AAHHS AAHQN AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFS ACPOU ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFWVQ AFZJQ AHBTC AI. AITYG AIURR AIWBW AJBDE AJXKR ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB AQPKS ASPBG ATUGU AUFTA AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMNLL BMXJE BNHUX BROTX BRXPI BY8 CS3 D-E D-F DCZOG DPXWK DR1 DR2 DRFUL DRSTM DU5 EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S G.N GNP GODZA H.T H.X HBH HF~ HGLYW HHY HHZ HVGLF HZ~ IX1 J0M JPC KQQ LATKE LAW LC2 LC3 LEEKS LH4 LH5 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG P2P P2W P2X P4D PALCI Q.N Q11 QB0 QRW R.K RIWAO RJQFR RNS ROL RWI RX1 RYL SAMSI SUPJJ SV3 UB1 V2E VH1 W8V W99 WBKPD WIB WIH WIK WJL WNSPC WOHZO WQJ WRC WRJ WXSBR WYISQ XG1 XPP XV2 Y6R ZGI ZXP ZZTAW ~IA ~KM ~WT AAYXX AEYWJ AGHNM AGQPQ AGYGG CITATION CGR CUY CVF ECM EIF NPM 7U5 8FD AAMMB AEFGJ AGXDD AIDQK AIDYY L7M 7X8 7S9 L.6 |
ID | FETCH-LOGICAL-c4380-e149754eb1aaf295e4d3d3c3e0867b318d2c7105bd19533331bfba1a2f9f2ca23 |
IEDL.DBID | DR2 |
ISSN | 0173-0835 1522-2683 |
IngestDate | Fri Jul 11 18:26:43 EDT 2025 Fri Jul 11 06:39:38 EDT 2025 Fri Jul 25 06:07:42 EDT 2025 Wed Feb 19 02:30:50 EST 2025 Tue Jul 01 04:03:09 EDT 2025 Thu Apr 24 22:54:57 EDT 2025 Wed Jan 22 16:37:15 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 22 |
Keywords | Dissociation constant Capillary electrophoresis Mass spectrometry Riociguat Fragmentation |
Language | English |
License | 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4380-e149754eb1aaf295e4d3d3c3e0867b318d2c7105bd19533331bfba1a2f9f2ca23 |
Notes | See article online to view Fig. 5 in color. Color online ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0001-7022-1317 0000-0001-8008-7668 |
PMID | 31520473 |
PQID | 2331794752 |
PQPubID | 2045162 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_2335128965 proquest_miscellaneous_2290901953 proquest_journals_2331794752 pubmed_primary_31520473 crossref_primary_10_1002_elps_201900181 crossref_citationtrail_10_1002_elps_201900181 wiley_primary_10_1002_elps_201900181_ELPS7050 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | November 2019 |
PublicationDateYYYYMMDD | 2019-11-01 |
PublicationDate_xml | – month: 11 year: 2019 text: November 2019 |
PublicationDecade | 2010 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany – name: Weinheim |
PublicationTitle | Electrophoresis |
PublicationTitleAlternate | Electrophoresis |
PublicationYear | 2019 |
Publisher | Wiley Subscription Services, Inc |
Publisher_xml | – name: Wiley Subscription Services, Inc |
References | 2015; 35 2017; 73 2010; 24 2010 2013; 73 2017; 11 2004; 25 2010; 398 2011; 22 2013; 773 2016; 128 2016 2014; 74 2018; 12 2005; 26 2018; 11 2006; 841 2015; 7 2016; 37 2004; 1037 2018; 57 e_1_2_7_6_1 e_1_2_7_5_1 e_1_2_7_4_1 e_1_2_7_3_1 e_1_2_7_9_1 e_1_2_7_7_1 e_1_2_7_19_1 e_1_2_7_18_1 e_1_2_7_17_1 e_1_2_7_2_1 e_1_2_7_15_1 e_1_2_7_14_1 Frisch M. J. (e_1_2_7_16_1) 2016 e_1_2_7_13_1 e_1_2_7_12_1 e_1_2_7_23_1 e_1_2_7_11_1 e_1_2_7_22_1 e_1_2_7_10_1 e_1_2_7_20_1 Zhang J. (e_1_2_7_8_1) 2018; 11 Lewars E. G. (e_1_2_7_21_1) 2010 |
References_xml | – volume: 11 start-page: 1195 year: 2017 end-page: 1207 publication-title: Drug Des. Devel. Ther. – volume: 11 start-page: 423 year: 2018 end-page: 430 publication-title: J. Clin. Exp. Med. – volume: 128 start-page: 882 year: 2016 end-page: 889 publication-title: Wien. Klin. Wochenschr. – volume: 37 start-page: 1591 year: 2016 end-page: 1608 publication-title: Electrophoresis – volume: 73 start-page: 891 year: 2017 end-page: 898 publication-title: Acta Cryst. Bs – volume: 74 start-page: 2065 year: 2014 end-page: 2078 publication-title: Drugs – volume: 841 start-page: 129 year: 2006 end-page: 134 publication-title: J. Chromatogr. B – volume: 398 start-page: 29 year: 2010 end-page: 52 publication-title: Anal Bioanal. Chem. – volume: 773 start-page: 24 year: 2013 end-page: 36 publication-title: Anal. Chim. Acta – volume: 1037 start-page: 445 year: 2004 publication-title: J. Chromatogr. A – volume: 24 start-page: 1025 year: 2010 end-page: 1031 publication-title: Rapid Commun. Mass Spectrom. – volume: 35 start-page: 502 year: 2015 end-page: 519 publication-title: Pharmacotherapy – volume: 57 start-page: 647 year: 2018 end-page: 661 publication-title: Clin. Pharmacokinet. – year: 2016 – volume: 12 start-page: 369 year: 2018 end-page: 374 publication-title: BioSci. Trends – volume: 25 start-page: 3080 year: 2004 end-page: 3085 publication-title: Electrophoresis – volume: 7 start-page: 193 year: 2015 end-page: 205 publication-title: Bioanalysis – volume: 22 start-page: 360 year: 2011 end-page: 368 publication-title: J. Am. Soc. Mass Spectrom. – volume: 73 start-page: 1967 year: 2013 end-page: 1975 publication-title: Drugs – volume: 26 start-page: 3221 year: 2005 end-page: 3231 publication-title: Electrophoresis – year: 2010 – ident: e_1_2_7_15_1 doi: 10.1002/elps.201600058 – ident: e_1_2_7_20_1 doi: 10.1016/j.jchromb.2006.03.015 – ident: e_1_2_7_6_1 doi: 10.2147/DDDT.S117277 – ident: e_1_2_7_19_1 doi: 10.1002/elps.200500260 – ident: e_1_2_7_2_1 – ident: e_1_2_7_18_1 doi: 10.1016/j.chroma.2004.02.087 – ident: e_1_2_7_11_1 doi: 10.1107/S2052520617006011 – ident: e_1_2_7_10_1 doi: 10.1007/s00508-016-1068-8 – ident: e_1_2_7_17_1 doi: 10.1002/elps.200405982 – volume-title: Gaussian 16 year: 2016 ident: e_1_2_7_16_1 – volume-title: Computational Chemistry: Introduction to the Theory and Applications of Molecular and Quantum Mechanics year: 2010 ident: e_1_2_7_21_1 – volume: 11 start-page: 423 year: 2018 ident: e_1_2_7_8_1 publication-title: J. Clin. Exp. Med. – ident: e_1_2_7_13_1 doi: 10.1007/s00216-010-3741-5 – ident: e_1_2_7_5_1 doi: 10.1002/phar.1592 – ident: e_1_2_7_3_1 doi: 10.1007/s40265-013-0149-5 – ident: e_1_2_7_7_1 doi: 10.1007/s40262-017-0604-7 – ident: e_1_2_7_22_1 doi: 10.1002/rcm.4458 – ident: e_1_2_7_9_1 doi: 10.4155/bio.14.257 – ident: e_1_2_7_23_1 doi: 10.1007/s13361-010-0037-0 – ident: e_1_2_7_4_1 doi: 10.1007/s40265-014-0317-2 – ident: e_1_2_7_12_1 doi: 10.5582/bst.2018.01081 – ident: e_1_2_7_14_1 doi: 10.1016/j.aca.2013.01.061 |
SSID | ssj0004944 |
Score | 2.3123815 |
Snippet | Riociguat is a novel antihypertensive drug for the treatment of pulmonary hypertension. We present electrophoretic characterization, i.e. migration behavior of... |
SourceID | proquest pubmed crossref wiley |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2936 |
SubjectTerms | antihypertensive agents buffers calibration Capillary electrophoresis dissociation Dissociation constant Electrolytes Electrophoresis, Capillary - methods formates Fragmentation Humans Hypertension ionic strength Ions Limit of Detection Linear Models Lithium lithium acetate Mass spectrometry Mass Spectrometry - methods Metabolites Parameter estimation Photometry Pyrazoles - analysis Pyrazoles - blood Pyrazoles - chemistry Pyrazoles - metabolism Pyrimidines - analysis Pyrimidines - blood Pyrimidines - chemistry Pyrimidines - metabolism Reproducibility of Results Riociguat Spectrometry Symmetry |
Title | Development of a CE‐MS method for the study of riociguat and metabolite M1 in pharmaceutical analysis |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Felps.201900181 https://www.ncbi.nlm.nih.gov/pubmed/31520473 https://www.proquest.com/docview/2331794752 https://www.proquest.com/docview/2290901953 https://www.proquest.com/docview/2335128965 |
Volume | 40 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LTxsxELYqLu2ltLSFtBS5ElJPho0f8fpYRUEIkariIXFb-bWAQJsIkgsnfkJ_I7-EmXV2SagKQuxxPV557Znx58d8Q8hm7DrvtfDMeemZzG1gubKOBW58NEaHWLPtD3_3do_l3ok6mYviT_wQ7YYbWkbtr9HArbvefiANjZdjpNuGCQ05p8AJ44UtREUHD_xR0shE7q0F0jCrhrUx49uL1RdnpX-g5iJyraeenWVim0anGycXW9OJ2_I3j_gcX_NXH8j7GS6lv5IifSRvYrVC3vabdHCfyOnc9SI6Kqml_cHd7d_hIU1JqCmgXwpoktaEtShxdQ4Dfzq1E2qrgFKgbxjxTIddel7R8dn8bjrIJHaUz-R4Z3DU32WzLA3MI1s9i7DG0kqCz7e25EZFGUQQXkRYLGkHLiNwDzBGuYAndvB0Xels1_LSlNxbLr6QpWpUxTVCbdClznId856XUJ4747yBj5Qqj6A0HcKaUSr8jMIcM2lcFol8mRfYfUXbfR3ys5UfJ_KO_0quN4NezIwYSqGt4K604h3yoy2GbsczFVvF0RRkuMkMBl2KJ2SEAFiVm57qkNWkUG1zBOCnTGqozWq1eKadxWD_z6HOVPb1hfLfyDt8maIo18nS5GoavwOcmriN2mTuAeIKGU0 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1Z3NbhMxEMdHVTmUC98fKQWMBOLkduNdx-sDB5SmSmlSIdpKvS2211sqqk3UJkJw4hF4FV6FR-BJmFnvbhsQIA49kKsnkWPPjP-7tn8D8NR3rXMqdty6xPEkNTlPpbE8F9p5rVXuK9r-eLc3PEheHcrDJfja3IUJfIj2hRtFRpWvKcDphfTGOTXUn0yJt40rGkGn6nOVO_7jB3xqO3uxvYlT_EyIrcF-f8jrwgLcEWCde3wsUDLBNGVMIbT0SR7nsYs96ntl0ctz4XDllTanTSb8dG1hTdeIQhfCGWIdYNa_QmXECde_-eacWJXoJODEVUzgZ9lwIiOxsdjfxXXwF3G7qJWrxW7rOnxrhimccXm_Pp_ZdffpJ4LkfzWON-BaLb3ZyxArN2HJl7dgpd9UvLsNRxdOULFJwQzrD75__jLeY6HONkOBz1Aws4rJSxanx-jbR3MzY6bMyQpDii51s3GXHZds-u7ihgHaBADMHTi4lP95F5bLSenvAzO5KlSUKp_2XILtqdXWafyRQqYe46IDvHGLzNWUdioWcpIFvrTIaLqydro68Ly1nwY-yW8t1xovy-o8ha3YV8zISooOPGmbcdhp28iUfjJHG6EjTfdK4z_YxDEqx1T3ZAfuBQ9uuxOjRIwShd_mlR_-pZ_ZYPR6T0UyWv1H-8ewMtwfj7LR9u7OA7hKBuHS6Bosz07n_iGqx5l9VMUrg7eX7dg_AC4mdsw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1Z3NbhMxEMdHVZGAC98fgQJGAnFyu_Ha8frAAeVDLW2qilKpt8VfW6pWm6hNhODEI_AovAqvwJMwXu9uGxAgDj2QqyeR154Z_ze2fwPwzHeNtTK11FhuKc-0o5nQhjqmrFdKOl_R9sfbvfU9_npf7C_B1-YuTORDtH-4hcio8nUI8Kkr1s6gof54GnDbuKAF5lR9rHLTf_yAL22nLzcGOMPPGRsN3_bXaV1XgNrAV6ce3wqk4JiltC6YEp671KU29SjvpUEnd8ziwiuMC3tM-OmawuiuZoUqmNUBdYBJ_xLvJSoUixi8OQNWccUjTVymgfssGkxkwtYW-7u4DP6ibRelcrXWja7Dt2aU4hGXo9X5zKzaTz8BJP-nYbwB12rhTV7FSLkJS768BVf6Tb2723Bw7vwUmRREk_7w--cv410Sq2wTlPcE5TKpiLzB4uQQPftgrmdEly5YYUCFK91k3CWHJZm-P79dgDYR_3IH9i7kOe_Ccjkp_X0g2slCJpn0Wc9ybM-MMlbhjxQi8xgVHaCNV-S2ZrSHUiHHeaRLszxMV95OVwdetPbTSCf5reVK42R5naWwFfuK-VgK1oGnbTMOe9g00qWfzNGGKXTz8GR_sElT1I2Z6okO3IsO3HYnRYGYcInfppUb_qWf-XBrZ1cmInnwj_ZP4PLOYJRvbWxvPoSroT3eGF2B5dnJ3D9C6Tgzj6toJfDuov36BzmkdXs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+a+CE%E2%80%90MS+method+for+the+study+of+riociguat+and+metabolite+M1+in+pharmaceutical+analysis&rft.jtitle=Electrophoresis&rft.au=%C5%A0t%C3%ADcha%2C+Martin&rft.au=Hlo%C5%BEek%2C+Tom%C3%A1%C5%A1&rft.au=Bursov%C3%A1%2C+Miroslava&rft.au=%C4%8Cabala%2C+Radom%C3%ADr&rft.date=2019-11-01&rft.issn=0173-0835&rft.eissn=1522-2683&rft.volume=40&rft.issue=22&rft.spage=2936&rft.epage=2945&rft_id=info:doi/10.1002%2Felps.201900181&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_elps_201900181 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0173-0835&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0173-0835&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0173-0835&client=summon |